SCHEMBL2656435

SCHEMBL2656435

Cc1nc(Cc2ccc(Cl)cc2Cl)co1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
LMNA P02545 3/20 0.47
RAB9A P51151 1/20 0.47
MAPT P10636 3/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
KDM4E B2RXH2 2/20 0.43
GAA P10253 1/20 0.43
IDO1 P14902 3/20 0.42
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPSR1 Q6W5P4 3/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HPGD P15428 1/20 0.39
P2RX7 Q99572 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11558189 0.76 SMN1; SMN2 (0.50) HTTSMN1; SMN2LMNARAB9AMAPT
SCHEMBL16016409 0.74 MPO (0.40) HTTSMN1; SMN2LMNAL3MBTL1ALDH1A1
SCHEMBL2656600 0.73 SMN1; SMN2 (0.50) HTTSMN1; SMN2LMNARAB9AMAPT
SCHEMBL2097653 0.72 IDO1 (0.65) HTTSMN1; SMN2LMNARAB9AMAPT
SCHEMBL21548891 0.71 SMN1; SMN2 (0.73) HTTSMN1; SMN2LMNARAB9AMAPT
SCHEMBL30075906 0.70 HSP90AA1 (0.51) LMNARAB9AMAPTMEN1KMT2A
SCHEMBL15497186 0.68 LMNA (0.67) HTTSMN1; SMN2LMNARAB9AMAPT
SCHEMBL10642788 0.67 SMN1; SMN2 (0.53) HTTSMN1; SMN2LMNARAB9AMAPT
SCHEMBL2262370 0.67 ENPP3 (0.44) SMN1; SMN2LMNARAB9AL3MBTL1GAA
SCHEMBL21727861 0.67 MEN1 (0.50) HTTSMN1; SMN2LMNARAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7196106-B2 Cyanothiophene derivatives, compositions containing such compounds and methods of use MERCK & CO., INC (US) 2007-03-27 US disclosed
US-7196106-B2 Cyanothiophene derivatives, compositions containing such compounds and methods of use MERCK & CO., INC (US) 2007-03-27 US disclosed
US-20040097552-A1 Cyanothiophene derivatives, compositions containing such compounds and methods of use MERCK SHARP & DOHME CORP. 2004-05-20 US disclosed
US-20040097552-A1 Cyanothiophene derivatives, compositions containing such compounds and methods of use MERCK SHARP & DOHME CORP. 2004-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097552-A1 Cyanothiophene derivatives, compositions containing such compounds and methods of use GLP1R, GPR119, GCGR HTT 3032/4885SMN1; SMN2 4289/4885LMNA 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.